Key Points
- Insider sale: Jonathan Zalevsky sold 1,157 Nektar shares on Nov. 25 at an average price of $54.28 (≈$62,802), trimming his holding to 18,971 shares — a 5.75% reduction in his position.
- Recent results: Nektar reported Q3 EPS of -$1.85, beating estimates of -$2.85, with revenue of $11.79M versus $10.2M, but the company still shows deeply negative profitability metrics (negative ROE and net margin).
- Stock context: Nektar has a market cap of ~$1.23B, a 52-week range of $6.45–$66.92 and 50/200-day moving averages of $58.30/$34.92, while analysts carry a consensus "Moderate Buy" and a $107.20 average price target.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Mark Andrew Wilson sold 630 shares of the company's stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total transaction of $34,196.40. Following the sale, the insider directly owned 21,585 shares in the company, valued at $1,171,633.80. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Nektar Therapeutics Price Performance
Shares of NKTR opened at $60.35 on Wednesday. The company has a market cap of $1.23 billion, a PE ratio of -6.86 and a beta of 1.19. The firm has a 50-day moving average of $58.30 and a 200-day moving average of $34.92. Nektar Therapeutics has a one year low of $6.45 and a one year high of $66.92.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.85) by $1.00. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. The business had revenue of $11.79 million during the quarter, compared to the consensus estimate of $10.20 million. Analysts expect that Nektar Therapeutics will post -0.72 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on NKTR shares. Wall Street Zen downgraded Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, November 16th. BTIG Research reaffirmed a "buy" rating and set a $100.00 price objective on shares of Nektar Therapeutics in a research report on Friday, September 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Nektar Therapeutics in a report on Wednesday, November 19th. B. Riley lifted their target price on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the stock a "buy" rating in a report on Tuesday, September 23rd. Finally, Jefferies Financial Group restated a "buy" rating and set a $121.00 price objective on shares of Nektar Therapeutics in a research report on Monday. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $107.20.
Read Our Latest Research Report on Nektar Therapeutics
Institutional Trading of Nektar Therapeutics
Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its position in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 210 shares in the last quarter. Algert Global LLC bought a new stake in shares of Nektar Therapeutics in the first quarter valued at approximately $33,000. US Bancorp DE grew its position in Nektar Therapeutics by 257.8% during the first quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 36,085 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Nektar Therapeutics during the 2nd quarter worth $39,000. Finally, Cerity Partners LLC bought a new position in Nektar Therapeutics during the 1st quarter worth $52,000. Institutional investors own 75.88% of the company's stock.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
